Banu A Karimi-Shah
Overview
Explore the profile of Banu A Karimi-Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bi Y, Rekic D, Paterniti M, Chen J, Marathe A, Chowdhury B, et al.
J Pharmacokinet Pharmacodyn
. 2020 Sep;
48(1):55-67.
PMID: 32949322
Pirfenidone and nintedanib are the first two FDA-approved therapies for treatment of idiopathic pulmonary fibrosis (IPF). The clinical programs for pirfenidone and nintedanib included 1132 patients in the placebo arms...
2.
Paterniti M, Bi Y, Rekic D, Wang Y, Karimi-Shah B, Chowdhury B
Ann Am Thorac Soc
. 2017 Apr;
14(9):1395-1402.
PMID: 28388260
Rationale: Exploration of FVC as it relates to mortality in idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and ultimately fatal parenchymal lung disease, is important both clinically and to the...
3.
Karimi-Shah B, Chowdhury B
N Engl J Med
. 2015 Mar;
372(13):1189-91.
PMID: 25806913
No abstract available.
4.
Tager A, LaCamera P, Shea B, Campanella G, Selman M, Zhao Z, et al.
Nat Med
. 2007 Dec;
14(1):45-54.
PMID: 18066075
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that...